US 11,858,905 B1
Cathepsin L inhibitors
Lichao Fang, Beijing (CN); Yayi Wang, Beijing (CN); Tianwei Ma, Beijing (CN); Ling Song, Beijing (CN); Zheng Huang, Beijing (CN); Jin-Kui Yang, Beijing (CN); and Shuo Gu, Beijing (CN)
Assigned to BIOFRONT THERAPEUTICS (BEIJING) CO., LTD., Beijing (CN); and RK PHARMTECH (BEIJING) LTD., Beijing (CN)
Filed by BIOFRONT THERAPEUTICS (BEIJING) CO., LTD., Beijing (CN); and RK PHARMTECH (BEIJING) LTD., Beijing (CN)
Filed on Mar. 31, 2023, as Appl. No. 18/194,609.
Claims priority of provisional application 63/478,502, filed on Jan. 5, 2023.
Int. Cl. C07D 263/56 (2006.01); C07D 413/12 (2006.01); C07D 413/04 (2006.01); C07D 231/56 (2006.01); C07D 277/64 (2006.01); A61P 31/14 (2006.01); C07D 413/14 (2006.01)
CPC C07D 263/56 (2013.01) [A61P 31/14 (2018.01); C07D 231/56 (2013.01); C07D 277/64 (2013.01); C07D 413/04 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01)] 20 Claims
 
1. A compound represented by formula (I-a):

OG Complex Work Unit Chemistry
wherein
R1 and R2 are independently selected from H, a —CH2— group, and an alkyl group;
R1 and R2 are unconnected or connected via a single bond;
W is CO or SO2;
R3 is an alkyl group, a fluoroalkyl group, a cycloalkyl group, an alkoxy group, an aryl group, a heteroaryl group, or a heterocyclic group, and R3 is optionally substituted by one or more groups selected from halogen, a hydroxyl group, an alkyl group, a fluoroalkyl group, a cycloalkyl group, an aryl group, a heterocyclic group, and an alkoxy group;
X1 is a CH group or N;
X2 is O, S, or N—R4, wherein R4 is selected from H, an alkyl group, an aryl group, and a heterocyclic group;
X3 is H, an alkyl group, a cycloalkyl group, an aryl group, a heteroaryl group, or a heterocyclic group, and X3 is optionally substituted by one or more groups selected from halogen, a hydroxyl group, an alkyl group, a fluoroalkyl group, a cycloalkyl group, and an alkoxy group;
Z1 is a CH group, C—R5, or N;
Z2 is a CH group, C—R6, or N;
Z3 is a CH group, C—R7, or N; and
Z4 is a CH group, C—R8, or N, wherein
R5—R8 are independently selected from H, halogen, a hydroxyl group, an alkyl group, a fluoroalkyl group, —CN, a cycloalkyl group, an alkoxy group, an aryl group, a heteroaryl group, and a heterocyclic group, and
each of R5-R8 is optionally substituted by one or more groups selected from halogen, a hydroxyl group, an alkyl group, a fluoroalkyl group, a cycloalkyl group, a heterocyclic group, a cycloalkyl group, an aryl group, and an alkoxy group.